Company: SION
Filing Date: 2025-05-12
Form Type: 10-Q
Source: 0002036042-25-000016
Chunk: 236

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-05-12
Form: 10-Q
Item: Part II, Item 8
Chunk 236
---
’s current and noncurrent marketable securities (in thousands):March 31, 2025AmortizedCost UnrealizedGainsUnrealizedLosses Fair ValueMarketable securities, current:U.S. Treasury securities$80,070 $192 $(1)$80,261 Commercial paper53,270 — (11)53,259 Government agency securities31,559 54 (3)31,610 Corporate debt21,838 5 (2)21,841 Total marketable securities, current186,737 251 (17)186,971 Marketable securities, noncurrent:U.S. Treasury securities74,455 61 — 74,516 Government agency securities10,500 6 — 10,506 Total marketable securities, noncurrent84,955 67 — 85,022 Total marketable securities$271,692 $318 $(17)$271,993 December 31, 2024Amortized CostUnrealized GainUnrealized LossFair ValueMarketable securities, current:U.S. Treasury securities$55,154 $176 $— $55,330 Government agency securities31,198 62 (1)31,259 Corporate debt17,205 22 — 17,227 Commercial paper5,931 3 — 5,934 Total marketable securities, current109,488 263 (1)109,750 Marketable securities, noncurrent:U.S. Treasury securities15,266 83 — 15,349 Government agency securities5,133 23 — 5,156 Total marketable securities, noncurrent20,399 106 — 20,505 Total marketable securities$129,887 $369 $(1)$130,255 The Company has determined that there were no material changes in the credit risk, therefore the Company has not recognized any allowance for credit losses on its debt securities. As of March 31, 2025, the Company holds marketable securities with an aggregate fair value of $85.0 million that had remaining maturities between one and two years. All other securities had a contractual maturity of less than a year. There were no realized gains or losses during the three months ended March 31, 2025, or 2024.

F-8

Table of Contents

4. Fair Value